{"product_id":"ferrlecit-sodium-ferric-gluconate-complex-sucrose-injection-62-5-mg-elemental-iron-5-ml-x-10-box","title":"Ferrlecit Sodium Ferric Gluconate Sucrose Injection 62.5 mg Elemental Iron 5 mL x 10\/Box (RX)","description":"\u003ch1\u003eFerrlecit (Sodium Ferric Gluconate Complex in Sucrose) Injection, 62.5 mg\/5 mL\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eFerrlecit is an intravenous iron‐replacement preparation (brand of sodium ferric gluconate complex). It is a colloidal carbohydrate‐stabilized iron solution; each 5 mL single‐dose vial delivers \u003cstrong\u003e62.5 mg elemental iron (12.5 mg\/mL)\u003c\/strong\u003e. In this formulation, ferric iron (Fe³⁺) is bound as a sodium ferric gluconate complex in a 20% sucrose solution (pH ~7.7–9.7). The solution has a characteristic deep red color due to ferric oxide linkages. Chemically, Ferrlecit is a high‐molecular‐weight (~300–440 kDa) iron‐gluconate complex. It provides a controlled release of iron to the body and contains benzyl alcohol (as a preservative), which precludes use in neonates. As an iron preparation, Ferrlecit’s purpose is to \u003cstrong\u003ereplete total-body iron stores\u003c\/strong\u003e when oral iron is inadequate.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eMechanism of Action:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eThe ferric iron in Ferrlecit is taken up by the reticuloendothelial system and slowly released to bind transferrin. Once bound to transferrin, the iron is delivered to the bone marrow for hemoglobin synthesis and to other tissues (including myoglobin and iron‐dependent enzymes). Iron is critical for hemoglobin to carry oxygen and for enzymatic reactions (e.g. ribonucleotide reductase for DNA synthesis). Administering Ferrlecit replenishes iron needed for red blood cell production in iron‐deficient patients. The carbohydrate (gluconate) and sucrose stabilize the ferric iron in solution, minimizing free “unbound” iron and reducing oxidative toxicity.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eClinical Uses:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eFerrlecit is FDA-approved for iron deficiency anemia in chronic kidney disease (CKD) patients on hemodialysis who are receiving erythropoiesis-stimulating agents. It is indicated for adults and for pediatric patients ≥6 years old with CKD on dialysis. By providing intravenous iron, Ferrlecit helps achieve adequate hemoglobin levels in patients who lose iron in dialysis and who do not absorb sufficient iron orally. In practice, it is often used when oral iron fails or cannot be tolerated. (Note: In adults without CKD, other IV iron products may be preferred; Ferrlecit’s labeled use is specific to dialysis patients on epoetin therapy.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eDosage and Administration:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eFerrlecit is administered \u003cstrong\u003eintravenously by slow injection or infusion\u003c\/strong\u003e under medical supervision. Important dosing and preparation points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose and Concentration:\u003c\/strong\u003e Each vial contains 62.5 mg elemental iron in 5 mL (12.5 mg\/mL). Because the usual adult dose is 125 mg, two vials (10 mL) are typically used per dialysis session.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdult dosing:\u003c\/strong\u003e The recommended adult dose for repletion is usually \u003cstrong\u003e125 mg elemental iron per session\u003c\/strong\u003e (often given as 10 mL). This can be administered either as:\n\u003cul\u003e\n\u003cli\u003e\n\u003cem\u003eIntravenous infusion:\u003c\/em\u003e 125 mg diluted in 100 mL of normal saline (0.9% NaCl) infused over ~60 minutes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cem\u003eSlow IV push:\u003c\/em\u003e 125 mg undiluted (in 10 mL) given slowly (no faster than 12.5 mg\/min).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePediatric dosing (≥6 years):\u003c\/strong\u003e Typically 1.5 mg\/kg (0.12 mL\/kg) elemental iron per session, diluted in 25 mL saline over 1 hour.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdministration precautions:\u003c\/strong\u003e Ferrlecit vials are \u003cem\u003esingle-dose\u003c\/em\u003e and contain benzyl alcohol preservative. Do \u003cstrong\u003enot\u003c\/strong\u003e mix Ferrlecit with any other drugs or IV solutions (including dextrose, calcium solutions, or parenteral nutrition). The only compatible diluent is 0.9% sodium chloride. Inspect the solution before use; it should be a clear, dark brown liquid without particulate. If diluted, use the solution immediately.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInfusion setup:\u003c\/strong\u003e Use dedicated IV line with normal saline; flush line before and after administration to avoid venous irritation. Do not administer Ferrlecit by any route other than intravenous.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTotal treatment course:\u003c\/strong\u003e Iron repletion often requires multiple doses. Clinically, a full replacement course may total ~1000 mg of elemental iron (e.g. 8 doses of 125 mg) administered over several dialysis sessions. Doses above 125 mg\/session are not recommended due to increased risk of reactions. Repeat treatment only if iron deficiency recurs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eAdverse Reactions (Side Effects):\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003eCommon reactions include \u003cstrong\u003egastrointestinal effects\u003c\/strong\u003e and injection-related symptoms. In clinical studies, ≥10% of adults reported: nausea, vomiting, diarrhea, injection-site reaction (pain, swelling), hypotension, muscle cramps (leg cramps), hypertension, dizziness, dyspnea (shortness of breath), chest pain, and leg cramps. In children (6–15 years), the most frequent (≥10%) were hypotension, headache, hypertension, tachycardia, and vomiting. Generally, reactions are mild-to-moderate; gastrointestinal symptoms and injection-site discomfort were common.\u003c\/p\u003e\n\u003ch2\u003eSerious Reactions and Precautions:\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypersensitivity\/Anaphylaxis:\u003c\/strong\u003e Although rare, \u003cstrong\u003eanaphylactic-type allergic reactions\u003c\/strong\u003e can occur (some life-threatening or fatal). These may manifest as chest pain, lightheadedness, rash, bronchospasm, or shock. \u003cstrong\u003eMonitoring\u003c\/strong\u003e: Patients must be monitored during and for at least 30 minutes after each dose. Treat immediately if an allergic reaction occurs (epinephrine, IV steroids, and supportive care at the ready). Do \u003cstrong\u003enot\u003c\/strong\u003e administer Ferrlecit if severe allergy to iron–carbohydrate complexes is known.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypotension:\u003c\/strong\u003e Acute drops in blood pressure can happen during or shortly after infusion. Monitor blood pressure and symptoms throughout infusion. If hypotension occurs, slow or stop the infusion until stabilized.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIron Overload:\u003c\/strong\u003e Avoid administering Ferrlecit when iron stores are already high. Regularly check hematologic indices (hemoglobin, ferritin, transferrin saturation). \u003cstrong\u003eContraindication\u003c\/strong\u003e: Do not give Ferrlecit to patients with existing iron overload. Overload may exacerbate organ damage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBenzyl Alcohol Toxicity:\u003c\/strong\u003e Ferrlecit contains benzyl alcohol (preservative). Premature or low-birth-weight infants are at risk of “gasping syndrome” if exposed to benzyl alcohol . Thus, Ferrlecit should not be used in neonates or infants, and caution is advised in pregnant patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy\/Lactation:\u003c\/strong\u003e Use in pregnancy only if clearly needed (“high risk” category). Hypersensitivity reactions can affect the fetus; benzyl alcohol is hazardous to the fetus. Breastfeeding is not recommended during treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOther Contraindications:\u003c\/strong\u003e Do not use in patients with known hypersensitivity to sodium ferric gluconate or any inactive ingredients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Side Effects Summary:\u003c\/strong\u003e These may include nausea, vomiting, diarrhea, headache, muscle cramps, dizziness, rash, pruritus, hypertension or hypotension, cough, and injection-site reactions. Most resolve within hours and are managed supportively. If severe symptoms arise, discontinue the dose and provide appropriate care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Points for Practitioners:\u003c\/strong\u003e Ferrlecit is a targeted IV iron therapy for dialysis patients. It should always be administered slowly with resuscitation measures available. Monitor patients’ vital signs and iron indices. Ensure the correct dose (62.5 mg\/vial) and follow dilution guidelines (normal saline only). Always inform patients about possible allergic reactions and instruct them to report any unusual symptoms immediately.\u003c\/p\u003e","brand":"Sanofi Aventis","offers":[{"title":"Default Title","offer_id":53791349178736,"sku":"00024-2792-10","price":499.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0996\/0350\/files\/Ferrlecit-Sodium-Ferric-Gluconate-Complex-Sucrose-Injection.jpg?v=1779209820","url":"https:\/\/www.mountainside-medical.com\/products\/ferrlecit-sodium-ferric-gluconate-complex-sucrose-injection-62-5-mg-elemental-iron-5-ml-x-10-box","provider":"Mountainside Medical","version":"1.0","type":"link"}